Lana Pine

Jeff Peterson, MD, explains the importance of the recent FDA announcement granting priority review of the Supplemental Biologics License Application for concomitant use of pegloticase injection (KRYSTEXXA) plus methotrexate for patients with uncontrolled gout.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 2, 2022.

Supported self-management approaches have been shown to benefit patients with chronic health conditions, including gout.

Influenza vaccination rates remain low within patients with rheumatoid arthritis. Investigators urge rheumatologists to encourage vaccination acceptance as a part of routine care.

Chronic stressors may play an important role in the development of chronic pain, leading to excess cortisol production and disruption to the body's sympathetic and parasympathetic systems.

“The effects of coffee consumption on SUA levels and gout risk are controversial,” investigators explained. “There have hitherto been no reports based on its effects that consider pleiotropy.”

“[Some] Patients may benefit from switching to a fully human biologic, such as IV-golimumab, to control disease activity/improve drug tolerance," investigators stated.

Patients with rheumatic disease were more likely to have a Pulmonary X-Ray Severity score >9, were more likely to require mechanical ventilation, and had a higher risk of death when compared with controls.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 26, 2021.

Iberdomide, a high-affinity cereblon modulator, works by affecting leukocyte development and autoimmunity.

Limited physical function, fatigue, mental health issues (resulting from chronic disease), and medication issues can further affect the ability of children with rheumatic disease from performing well in school.

Recent studies suggest that a gap in cardiovascular risk remains between patients with rheumatoid arthritis and the general population.

A retrospective study analyzed patients with systemic sclerosis to determine prevalence, severity, and mortality within this patient population.

“Understanding the impact of axSpA on pregnancy outcomes is a vital component of improving management of women with axSpA at every stage of their lives,” investigators stated.

“Incorporating patient perspectives will not only help better tailor therapies in this heterogeneous population but also identify treatment targets that are relevant to the individual patients," investigators explained.

“Access to mental health services is a critical component of comprehensive care for patients suffering from rheumatologic disease,” investigators stated.

Karen Onel, MD, one of the lead investigators of the ACR's recent JIA treatment guidelines updates, explains important changes, treating patients with glucocorticoids, and the continued unmet needs in pediatric rheumatology.

Soumya D. Chakravarty, MD, PhD, discusses the growing body of clinical evidence evaluating joint efficacy, safety, and patient-reported outcomes in patients with psoriatic arthritis receiving guselkumab.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 12, 2021.

Daniel J. Lovell, MD, MPH, explains the recent ACR guidelines updates regarding the treatment and management of juvenile idiopathic arthritis and the clinical significance of the changes.

Roy Fleischmann, MD, discusses the usage of biosimilars in the United States and hypothesizes about what is in store for the future.

Roy Fleischmann, MD, examines the current state of biosimilars as it relates to rheumatologists in the United States.

Roy Fleischmann, MD, explains the history of biosimilars in rheumatology as well as implementing biosimilars in the United States.

Titled, "Biosimilars in Rheumatology: Past, Present, and Future," this 3-part video series explores the origins of biosimilars, where we are currently, and hypothesizes about the future of biosimilars in the United States.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 5, 2021.

The American College of Rheumatology (ACR) has published guidance regarding the management of juvenile idiopathic arthritis, with emphasis placed on the treatment of systemic JIA and oligoarthritis, as well as non-pharmacologic therapies.

Aspartyl-alanyl-diketopiperazine (Ampion), an intra-articular injection, works to regulate immune responses that are connected to pain, inflammation, and joint damage in patients with osteoarthritis of the knee.

In rheumatoid arthritis, a treat-to-target approach aims for remission or low disease activity within the first 3 months. However, investigators noted that improvements continued to increase throughout the 52-week period.

Rheumatology Network interviewed Jeffrey Stark, MD, to discuss the BE COMPLETE study, which examined the efficacy of bimekizumab for treating psoriatic arthritis.

The long-term success of any psoriatic arthritis treatment may be predictable as early as 3 months if a timely assessment and adjustment of disease management is prioritized.